Fact Sheet

Accelerating Precision Bioanalysis for Obesity and Type 2 Diabetes Drug Development

As the global pipeline for obesity and type 2 diabetes (T2D) therapeutics expands — driven by GLP-1 analogs, agonists, dual agonists and next generation peptide drugs — pharmaceutical and biotech companies can gain a competitive advantage by partnering with bioanalytical laboratories that can deliver expertise in high-sensitivity, regulatory-compliant liquid chromatography mass spectrometry (LC-MS) assays.



At IQVIA Laboratories Biosciences, we combine state-of-the-art LC-MS methodology with decades of scientific expertise to support every phase of metabolic drug development. Our holistic, science-led approach ensures each assay is precisely tailored to the drug's molecular structure, optimizing analyte extraction, LC separation, and MS detection. From early discovery and ADME (absorption, distribution, metabolism and excretion) profiling to clinical trial bioanalysis, we deliver the accuracy, reproducibility, and speed needed to move your program forward.

Specialized bioanalytical services for metabolic drug development, preclinical to clinical

- GLP-compliant LC-MS bioanalysis.
- Metabolite identification and ADME studies.
- High-sensitivity assays for peptide and protein therapeutics.
- Biomarker profiling for precision medicine.
- Triple quadrupole (QqQ) and high-resolution mass spectrometry (HRMS) platforms.

Why leading pharma and biotechs are choosing IQVIA Laboratories

An expanding array of weight reducing drugs in development (currently >170 obesity-related therapies[1]) calls for deep experience in scalable bioanalytical support.

The logistical capabilities and instrumentation capacity to handle associated large T2D and obesity clinical trials.

Expertise in managing complex peptide structures (GLP-1/GIP agonists, DPP-4 inhibitors) and bioanalytical techniques to develop, validate and apply regulatory compliant quantitative assays.

Proven track record supporting PK/PD modeling, drug-drug interaction studies, and regulatory submissions.

[1]Citeline Trialtrove, Jan 2025; IQVIA Institute, Jan 2025



Technical capabilities at a glance

CAPABILITY	DETAILS
Sample preparation	High throughput 96-well automation leveraging SPE, liquid-liquid and protein precipitation strategies customized to specific assays needs.
LC-MS platforms	Thermo Q-Orbitrap HRMS, Vanquish Horizon UHPLC and Sciex QqQ.
Flow rates	Micro-flow (<100 µL/min) for enhanced sensitivity.
Analyte types	Peptides, proteins, small molecule, metabolites.
Study phases	Discovery → Preclinical (TK/PK) → Clinical trials.

Proven results in obesity and T2D drug development

- Enabled ultra-sensitive detection of GLP-1 agonists/analogs and DPP-4 inhibitors.
- Delivered customized assays for dual agonists.
- Drug-drug interaction risk assessment.

Ready to accelerate your obesity or T2D drug program?

Don’t let bioanalytical complexity slow your progress. Partner with IQVIA Laboratories Biosciences to gain a strategic edge in drug development. Our LC-MS expertise, regulatory know-how, and proven success in peptide and biomarker analysis make us the ideal lab partner for your next breakthrough.

Contact us today and let’s move your molecule forward — faster, smarter, and with confidence.

IQVIA LABORATORIES

CONTACT US
U.S.: +1 833 793 5298
UK: +44 800 028 9326
BioAinfo@iqvia.com
labs.iqvia.com